SEC Form 4 · accession 0001209191-15-001712
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul B Cleveland
Officer — President and CFO
Period of report
Jan 1, 2015
Accepted (ET)
Jan 5, 2015 · 8:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1,F2 | $19.53 | Jan 1, 2015 | A | 140,000 | A | Jan 1, 2016 | Dec 31, 2024 | Common Stock | 140,000 | 417,500 | D |
Explanation of responses
- F1Grant of stock option under the Issuer's 2013 Equity Incentive Plan.
- F225% of the shares subject to the option vest and become exercisable on the one year anniversary of January 1, 2015 (the "Vesting Commencement Date"), and 1/48th of the shares vest in equal monthly installments thereafter, over the remaining three years.